1.40
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death - MSN
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells - USA Today
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - Daily Commercial
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Telomir Pharmaceuticals Inc. stock attracts high net worth investorsTrade Signal Summary & Free Community Supported Trade Ideas - Newser
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 2.3% – Still a Buy? - Defense World
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 Chart Watch & Real-Time Volume Triggers - moha.gov.vn
Telomir Pharmaceuticals announces new preclinical data on Telomir-1 - MSN
Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support - marketscreener.com
Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data - MSN
Telomir reports PSA reduction in prostate cancer cells with lead drug - Investing.com Nigeria
Telomir reports PSA reduction in prostate cancer cells with lead drug By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Reports Promising Preclinical Data - TipRanks
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event | TELO SEC FilingForm 8-K - Stock Titan
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells - Bluffton Today
Will Telomir Pharmaceuticals Bounce Back? - StocksToTrade
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025 - ts2.tech
Telomir stock surges after leukemia cell-killing data By Investing.com - Investing.com Nigeria
Telomir stock surges after leukemia cell-killing data - Investing.com UK
Telomir Pharma (NASDAQ: TELO) Telomir-1 Shows Preclinical HL60 Leukemia Activity - Stock Titan
Telomir Pharmaceuticals director Craig Eagle resigns from board By Investing.com - Investing.com Australia
Telomir Pharmaceuticals director Craig Eagle resigns from board - Investing.com
Telomir Pharmaceuticals Inc. Announces Resignation of Craig Eagle as Director, Effective on November 14, 2025 - MarketScreener
Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy - TipRanks
Telomir Pharmaceuticals, Inc. Announces Telomir-1 Kills Aggressive Human Leukemia Cells - marketscreener.com
How Telomir Pharmaceuticals Inc. stock performs after earnings2025 Market Overview & Precise Buy Zone Tips - newser.com
Does Telomir Pharmaceuticals Inc. stock trade at a discount to peersQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Will Telomir Pharmaceuticals Inc. bounce back from current supportMarket Activity Recap & Precise Buy Zone Tips - newser.com
Has Telomir Pharmaceuticals Inc. found a price floorJuly 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com
Telomir Pharmaceuticals Completes $2.9 Million Stock Sale - MSN
Analyzing Telomir Pharmaceuticals Inc. with risk reward ratio charts2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):